Front Page News
Biogen and Ionis Release Spring 2016 Community Update
Biogen and Ionis Pharmaceuticals recently provided an update on the clinical development of nusinersen (IONIS-SMNRx), which is currently being tested in Phase 3 clinical trials: […]
Read More ›2016 Update on SMA-FDA Interactions
The SMA drug pipeline has grown dramatically in just over a decade. Of the 18 programs in the pipeline, six of these are in clinical […]
Read More ›2016 Annual SMA Conference Booklet Now Posted
The 2016 Annual SMA Conference Booklet has been posted. The booklet includes: A complete schedule with information about the special events we’ve got planned for […]
Read More ›Update on the Clinical Development of LMI070
Novartis recently provided the following update on clinical trials for LMI070, an orally available SMA drug that corrects SMN2 splicing: “We have made the difficult […]
Read More ›Spring 2016 Issue of Compass Now Available
The Spring 2016 issue of Compass is now available online. As part of our most recent round of funding, we’ve announced eight grants totaling $890,000 […]
Read More ›Cure SMA Awards $300,000 Drug Discovery Grant to Charlotte Sumner, in Collaboration with Imago Pharmaceuticals
Cure SMA has awarded a $300,000 drug discovery grant to Charlotte Sumner, MD, at Johns Hopkins University, in collaboration with Imago Pharmaceuticals. The award is […]
Read More ›Announcing an Evening of Fun at Disneyland Park
Just added to this year’s conference schedule: Saturday Night at Disneyland Park! We’re very excited to announce that conference attendees will get to take part […]
Read More ›Cure SMA Releases Full Schedule for the 2016 Annual SMA Conference
Cure SMA has released the full schedule for the 2016 Annual SMA Conference, which will be held in Anaheim, CA at Disneyland, June 16-19. The […]
Read More ›Cure SMA Awards $70,000 Grant to Christine DiDonato, Lurie Children’s Hospital of Chicago
Cure SMA has awarded a $70,000 research grant to Dr. Christine DiDonato at Lurie Children’s Hospital of Chicago for her project, “Assessing mediators of muscle […]
Read More ›AveXis Reports Data from Ongoing Phase 1 Trial of AVXS-101 in Spinal Muscular Atrophy Type 1
Today, AveXis, Inc. presented an interim analysis of data as of April 1, 2016 from the ongoing Phase 1 trial of AVXS-101 for the treatment […]
Read More ›